Calidi Biotherapeutics earnings release, May 14, 2026

Calidi Biotherapeutics, Inc. (CLDI) · Form 8-K, Item 2.02 · Filed · SEC filing

Exhibit

99.1

Calidi

Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights

SAN

DIEGO, May 14, 2026 — (GLOBE NEWSWIRE) — Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today reported its first quarter 2026 operating and financial results and reviewed recent business highlights.

“We are excited about the continued progress at Calidi,” said Eric Poma, PhD, Calidi Biotherapeutics CEO. “We continue to advance

CLD-401, the first lead from our RedTail platform, towards the clinic and have built a world-class scientific advisory board to aid those efforts. We have also expanded what the RedTail platform can do with our new approach of in situ T-cell engagers.”

First

Quarter 2026 and Recent Corporate Developments

First

Quarter 2026 Financial Results

The

Company reported a net loss attributable to common stockholders of $4.4 million, or $0.43 per share, for the three months ended March 31, 2026, compared to a net loss attributable to common stockholders of $5.0 million, or $2.21 per share, for the same period in 2025.

Research and development expenses were $2.6 million for the three months ended March 31, 2026, compared to $2.4 million for the comparable period in 2025.

General and administrative expenses were $1.6 million for the three months ended March 31, 2026, compared to $2.6 million for the comparable period in 2025.

The

Company had approximately $6.6 million in cash and $0.2 million in restricted cash as of March 31, 2026, compared to $5.6 million in cash and $0.2 million in restricted cash as of December 31, 2025.

About

Calidi Biotherapeutics

Calidi

Biotherapeutics (NYSE American: CLDI) is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The Company’s proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. This advanced enveloped technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations.

CLD-401, the lead candidate from the RedTail platform, currently in IND-enabling studies, targets non-small cell lung cancer, head and neck cancer, and other tumor types with high unmet medical need. Calidi continues to advance its pipeline utilizing the RedTail platform including its novel approach to incorporate in situ T-cell engagers in solid tumors.

Calidi

Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com or view Calidi’s

Corporate Presentation here.

Forward-Looking

Statements

Financial statements

Income Statement

Three Months Ended March 31, — (In thousands, except per share data)

Three Months Ended March 31, – 2026 – (Unaudited)Three Months Ended March 31, – 2025 – (Unaudited)
OPERATING EXPENSESResearch and development-2,587-2,425
OPERATING EXPENSESGeneral and administrative-1,600-2,637
OPERATING EXPENSESTotal operating expense-4,187-5,062
OPERATING EXPENSESLoss from operations-4,187-5,062
OTHER INCOME, NETInterest expense-33-34
OTHER INCOME, NETInterest expense – related party-5-38
OTHER INCOME, NETChange in fair value of other liabilities and derivatives4532
OTHER INCOME, NETChange in fair value of other liabilities and derivatives – related party33
OTHER INCOME, NETGrant income50
OTHER INCOME, NETOther income (expense), net73-10
OTHER INCOME, NETTotal other income, net833
OTHER INCOME, NETLOSS BEFORE INCOME TAXES-4,104-5,059
OTHER INCOME, NETIncome tax provision-4-3
OTHER INCOME, NETNET LOSS-4,108-5,062
OTHER INCOME, NETNet loss attributable to noncontrolling interest-76
OTHER INCOME, NETNET LOSS ATTRIBUTABLE TO CONTROLLING INTEREST-4,108-4,986
OTHER INCOME, NETDeemed dividend on warrants-309
OTHER INCOME, NETNET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS-4,417-4,986
OTHER INCOME, NETNet loss per share; basic and diluted-0.43-2.21
OTHER INCOME, NETWeighted average common shares outstanding; basic and diluted10,3082,257

Balance Sheet

March 31, 2026 — ( In thousands, except for par value data )

March 31, 2026 – (Unaudited)December 31, 2025
CURRENT ASSETSCash6,6315,600
CURRENT ASSETSPrepaid expenses and other current assets722656
CURRENT ASSETSTotal current assets7,3536,256
NONCURRENT ASSETSMachinery and equipment, net758781
NONCURRENT ASSETSOperating lease right-of-use assets, net1,3421,682
NONCURRENT ASSETSOther noncurrent assets138138
NONCURRENT ASSETSTOTAL ASSETS9,5918,857
CURRENT LIABILITIESAccounts payable849595
CURRENT LIABILITIESRelated party accounts payable5118
CURRENT LIABILITIESAccrued expenses and other current liabilities1,3131,276
CURRENT LIABILITIESRelated party accrued expenses and other current liabilities119530
CURRENT LIABILITIESFinance lease liability, current154111
CURRENT LIABILITIESOperating lease right-of-use liability, current1,3501,405
CURRENT LIABILITIESTotal current liabilities3,8363,935
NONCURRENT LIABILITIESOperating lease right-of-use liability, noncurrent6277
NONCURRENT LIABILITIESFinance lease liability, noncurrent147171
NONCURRENT LIABILITIESPromissory note600600
NONCURRENT LIABILITIESWarrant liability62107
NONCURRENT LIABILITIESRelated party warrant liability58
NONCURRENT LIABILITIESTOTAL LIABILITIES4,6565,098
NONCURRENT LIABILITIESTOTAL EQUITY4,9353,759
NONCURRENT LIABILITIESTOTAL LIABILITIES AND TOTAL EQUITY9,5918,857
Full release

This press release may contain forward-looking statements for purposes of the “safe harbor” provisions under the United States

Private Securities Litigation Reform Act of 1995. Terms such as “anticipates,” “believe,” “continue,”

“could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,”

“possible,” “potential,” “predicts,” “project,” “should,” “towards,”

“would” as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, the Company’s plans strategies, priorities and key operational initiatives for fiscal year 2026, including the Company’s plan to submit an Investigational New Drug (“IND”) application by the end of 2026, statements concerning key milestones, including certain pre-clinical data, planned clinical trials, and statements relating to the safety and efficacy of Calidi’s therapeutic candidates in development. Any forward-looking statements contained in this discussion are based on Calidi’s current expectations and beliefs concerning future developments and their potential effects and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that

Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials, the risk that early results of clinical trials do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive review of the data, and as more patient data becomes available, the risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates; and, with respect to the Company’s fiscal year 2026 initiatives, including the timing and ability to submit an IND application by the end of 2026, the risk that actual results may differ materially due to, among other things, the timing, cost and results of research and development activities and preclinical studies; interactions with, and the timing and substance of feedback from, regulatory authorities (including that any preliminary interactions with the FDA may not be indicative of future outcomes or regulatory success); changes in applicable laws or regulations; manufacturing and supply chain matters; the availability of capital and other resources; and changes in business, market, economic or competitive conditions. Other risks and uncertainties are set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s annual report filed with the SEC on Form 10-K on March 27, 2026, as may be amended or supplemented by other reports we file with the... (truncated)cumstances after the date of this press release or to reflect the occurrence of unanticipated events.

Contacts:

For

Investors:

IR@calidibio.com

For

Media:

PR@calidibio.com

CALIDI

BIOTHERAPEUTICS, INC.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Calidi Biotherapeutics earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.